To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT05495568 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

367

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Chronic Plaque Psoriasis

Interventions

BIOLOGICAL: CT-P17
BIOLOGICAL: EU-approved Humira

Sponsor

Celltrion